Sagent Pharmaceuticals Announces the Launch of Docetaxel Injection Concentrate
July 31, 2013 19:02 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., July 31, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the launch of Docetaxel Injection Concentrate, an antineoplastic agent, in three...
Sagent Pharmaceuticals Sets Date and Time for Release of Second Quarter 2013 Financial Results
July 23, 2013 18:22 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., July 23, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Appoints Michael Fekete to Its Board of Directors
July 11, 2013 16:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., July 11, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Expands a Nationwide Voluntary Recall to All Lots of Vecuronium Bromide for Injection, 10mg Single Use Vials Manufactured by Mustafa Nevzat (MN Pharmaceuticals)
June 13, 2013 09:45 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., June 13, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the expanded voluntary nationwide recall of Vecuronium Bromide for Injection 10mg...
Sagent Pharmaceuticals Initiates a Nationwide Voluntary Recall of Three Lots of Vecuronium Bromide for Injection, 10mg Manufactured by Mustafa Nevzat (MN Pharmaceuticals) Due to Elevated Impurity Levels
June 07, 2013 11:37 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., June 7, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced the voluntary nationwide recall of three lots of Vecuronium Bromide for Injection 10mg...
Sagent Pharmaceuticals Announces Agreement to Acquire Remaining 50% Interest in Chinese Manufacturing Joint Venture
May 06, 2013 07:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., May 6, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Reports First Quarter 2013 Financial Results
May 06, 2013 07:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., May 6, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced...
Sagent Pharmaceuticals Sets Date and Time for Release of First Quarter 2013 Financial Results
April 24, 2013 08:00 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., April 24, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today...
Sagent Pharmaceuticals Appoints James M. Hussey as President
March 19, 2013 17:36 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., March 19, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today...
Sagent Pharmaceuticals Announces Amendment to Supply Agreement With Actavis, Inc.
March 05, 2013 17:14 ET
|
Sagent Pharmaceuticals, Inc.
SCHAUMBURG, Ill., March 5, 2013 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader in specialty injectable pharmaceutical products, today announced the signing of an amendment to...